Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
329.40
-13.10 (-3.82%)
Feb 18, 2026, 5:24 PM IDT
Market Cap823.52M +868.0%
Revenue (ttm)n/a
Net Income-42.05M
EPS-1.79
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,688
Average Volume150,612
Open342.50
Previous Close342.50
Day's Range329.30 - 342.50
52-Week Range213.20 - 682.90
Beta1.59
RSI52.65
Earnings DateMar 30, 2026

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 71
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements